Did you even watch the segment? She asked him if there was anything on the horizon and he spoke of mabs but only antiviral to help the severely ill. And since, as we here believe, those aren't useful for severe or critical cases that have progressed to the hyperimmune phase, he was aiming at the wrong target. That's what bothered me the most.

And when she asked, he said there might be a different therapeutic way down the road, and talked about starting out in animal models and then on to Phase 1 trials, etc. It wasn't that he didn't name LL (which I would have loved but didn't at all expect) that really got to me, but that he didn't talk about immune system treatments as a class at all, when it seems they are the most promising treatments for the s/c class of cases.